binimetinib,crizotinib,palbociclib,axitinib,encorafenib
ono Pharmaceuticalscueticals,pierre fabre,pfizer
['mektovi', 'braftovi', 'inlyta', 'ibrance', 'xalkori', 'pfizer']
 #oncology growth is driven by stellar #portfolio comprising inlyta, ibrance, xalkori, braftovi, mektovi, to name a few. pfizer accounted for a 17% cagr between 2010-2021, in the global oncology #prescription market. it is exciting to see #whatsnext #esmo22 
A healthcare-focused strategy consulting firm, providing bench-to-bedside decision support to pharmaceutical, biotech, and medical device companies